权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mutant ER and Loss of Response for Hormone Therapy in Breast Cancer

乳腺癌中 ER 突变和激素治疗失去反应

基本信息

批准号：
06671218
负责人：
KIMIJIMA Izo
金额：
$ 1.34万
依托单位：
Fukushima Medical College
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1994
资助国家：
日本
起止时间：
1994 至 1995
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-06671218/
关键词：
BREAST CANCER PCR SSCP ESTROGENE RECEPTOR MUTATION pS2 ミュータント

项目摘要

We have done 2 kind of study.1. ER gene variantWe in vestigated the gene variants at exon 2 and 7 of Estrogene Receptor (ER) gene in 44 breast cancer cases in 1994. Furthermore, in 1995, we increased range and case number and in vestigated gene variant.[Materials and Methods] We extr942ed DNA from 99 breast cancer tissues which were frozen immediately after resection, and evaluated the variant at exon 2,3,4,5,7 by PCR-SSCP method.[Results] Sixteen variants were detected in 99 cases. There was no correlation between ER gene variant and Tum-stage, ER,PgR,pS2 protein, p53 or pathological classification. But there was significant correlation between variant and aneuploid, and therfore only one c-erbB-2 positive case was variant in evaluated 15 cases. Overall survival was better in the variant negative group than in the variant positive group, but it was not significant. Overall survival was significantly low in the group with valiant at both exon 3 and 7 than in the group with out variant.2. pS2 expression[Materials and Methods] We evaluated the pS2 protein expression in 305 women with primary breast cancer by immunohistochemical method and compare it with their other clinicopathological factors.[Results] There was no significant correlation between the pS2 expression and tumor size, lymphnode status, metastasis, stage, histological classification, ploidy, p53 or cerbB-2. The pS2 protein expression has significant positive correlation with ER and PgR,the latter (P<0.0001) has stronger significance than the former (P=0.0004). Overall survival was significantly (P=0.0035) better in the pS2 positive group than that in the negative group. This study suggests that the pS2 protein will act as a favorable prognostic factor survival and its positivity has potential to indicate the candidate for hormone therapy.

我们做了两种研究：1。 ER基因变异我们于1994年在44例乳腺癌病例中研究了雌激素受体（ER）基因第2和第7外显子的基因变异。此外，我们于1995年扩大了研究范围和病例数，并增加了研究基因变异的范围。[材料与方法]我们从99例切除后立即冷冻的乳腺癌组织中提取942ed DNA，并评估了第2、3、4、5、7外显子的变异。 [结果]99例中检出16个变异。 ER基因变异与Tum分期、ER、PgR、pS2蛋白、p53及病理分类无相关性。但变异与非整倍体之间存在显着相关性，因此在评估的15例中仅1例c-erbB-2阳性病例存在变异。变异阴性组的总生存率优于变异阳性组，但并不显着。外显子 3 和 7 均具有 valant 的组的总生存率显着低于不具有 variant 的组。2． pS2表达[材料与方法]我们采用免疫组织化学方法评估了305例女性原发性乳腺癌的pS2蛋白表达，并与其他临床病理因素进行比较。[结果]pS2表达与肿瘤大小、淋巴结状态、转移、分期、组织学分类、倍性、p53或cerbB-2之间没有显着相关性。 pS2蛋白表达与ER、PgR呈显着正相关，后者(P<0.0001)显着性强于前者(P=0.0004)。 pS2 阳性组的总生存率显着优于阴性组（P=0.0035）。这项研究表明，pS2 蛋白将作为生存的有利预后因素，其阳性有可能表明激素治疗的候选者。